Using human CD20-transfected murine lymphomatous B cells to evaluate the efficacy of intravitreal and intracerebral rituximab injections in mice

Investigative Ophthalmology and Visual Science

Volumn 49, Issue 11, 2008, Pages 4738-4745

  Mineo, Jean François ^a   Scheffer, Aymeric ^a   Karkoutly, Céline ^a   Nouvel, Lisa ^a   Kerdraon, Olivier ^a   Trauet, Jacques ^a   Bordron, Anne ^b   Dessaint, Jean Paul ^a   Labalette, Myriam ^a   Berthou, Christian ^b   Labalette, Pierre ^a  

^a UNIV LILLE   (France)

^b Laboratory of Cell Therapy and Haematology   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CD20 ANTIGEN; RITUXIMAB; TRASTUZUMAB; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; B CELL LYMPHOMA; CANCER INHIBITION; CAUDATE NUCLEUS; CILIARY DISK; CONTROLLED STUDY; DRUG EFFICACY; EXOPHTHALMOS; GENETIC TRANSFECTION; GRAFT RECIPIENT; HISTOLOGY; IMMUNOCOMPETENCE; INOCULATION; MOUSE; NEUROLOGIC DISEASE; NONHUMAN; OPHTHALMOSCOPY; PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA; PRIMARY INTRAOCULAR LYMPHOMA; PRIORITY JOURNAL; STEREOTACTIC PROCEDURE; TUMOR GROWTH; VITREOUS BODY; WEIGHT REDUCTION; ANIMAL; BIOSYNTHESIS; BRAIN; BRAIN TUMOR; C3H MOUSE; COMPARATIVE STUDY; EXPERIMENTAL NEOPLASM; FLOW CYTOMETRY; IMMUNOHISTOCHEMISTRY; IMMUNOLOGY; INJECTION; LARGE CELL LYMPHOMA; METABOLISM; PATHOLOGY; TREATMENT OUTCOME; TUMOR CELL LINE;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD20; ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; CELL LINE, TUMOR; CEREBRUM; FLOW CYTOMETRY; IMMUNOHISTOCHEMISTRY; INJECTIONS; LYMPHOMA, LARGE B-CELL, DIFFUSE; MICE; MICE, INBRED C3H; NEOPLASMS, EXPERIMENTAL; TREATMENT OUTCOME; VITREOUS BODY;

EID: 56149119567     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.07-1494     Document Type: Article

References (46)

1. Batchelor T, Loeffler JS. Primary CNS lymphoma. J Clin Oncol. 2006;24:1281-1288.
2. Bataille B, Delwail V, Menet T, et al. Primary intracerebral malignant lymphoma: report of 248 cases. J Neurosurg. 2000;92:261-266. (Pubitemid 30071045)
3. Commins DL. Pathology of primary central nervous system lymphoma. Neurosurg Focus. 2006;21:E2.
4. Schabet M. Epidemiology of primary CNS lymphoma. J Neurooncol. 1999;43:199-201.
5. Hochberg GF, Baehring JM, Hocberg EP. Primary CNS lymphoma. Nat Clin Pract Neurol. 2007;3:24-35.
6. Kadoch C, Treseler P, Rubenstein JL. Molecular pathogenesis of primary central nervous system lymphoma. Neurosurg Focus. 2006;21(5):E1.
7. Ferreri AJ, Blay JY, Reni M, et al. Prognostic scoring system for primary CNS lymphomas: the International Extranodal Lymphoma Study Group experience. J Clin Oncol. 2003;21:266-272. (Pubitemid 46606155)
8. Fisher B, Seiferheld W, Schultz C, et al. Secondary analysis of Radiation Therapy Oncology Group study (RTOG) 9310: an intergroup phase II combined modality treatment of primary central nervous system lymphoma. J Neurooncol. 2005;74:201-205. (Pubitemid 41478919)
9. Omuro AM, Abrey LE. Chemotherapy for primary central nervous system lymphoma. Neurosurg Focus. 2006;21(5):E12.
10. Poortmans PM, Kluin-Nelemans HC, Haaxma-Reiche H, et al. High-dose methotrexate-based chemotherapy followed by consolidating radiotherapy in non-AIDS-related primary central nervous system lymphoma: European Organization for Research and Treatment of Cancer Lymphoma Group Phase II Trial 20962. J Clin Oncol. 2003;21:4483-4488. (Pubitemid 46594017)
11. Gunduz K, Pulido JS, McCannel CA, O'Neill BP. Ocular manifestations and treatment of central nervous system lymphomas. Neurosurg Focus. 2006;21(5):E9.
12. Abrey LE, DeAngelis LM, Yahalom J. Long-term survival in primary CNS lymphoma. J Clin Oncol. 1998;16:859-863. (Pubitemid 28108717)
13. Chan CC, Wallace DJ. Intraocular lymphoma: update on diagnosis and management. Cancer Control. 2004;11:285-295. (Pubitemid 40310583)
14. Levy-Clarke GA, Chan CC, Nussenblatt RB. Diagnosis and management of primary intraocular lymphoma. Hematol Oncol Clin North Am. 2005;19:739-749. (Pubitemid 41096717)
15. Coiffier B. Treatment of non-Hodgkin's lymphoma: a look over the past decade. Clin Lymphoma Myeloma. 2006;(suppl 1):S7-S13.
16. Maloney DG. Immunotherapy for non-Hodgkin's lymphoma: monoclonal antibodies and vaccines. J Clin Oncol. 2005;23:6421-6428. (Pubitemid 46218853)
17. Vajkoczy P, Schilling L, Ullrich A, Schmiedek P, Menger M. Characterization of angiogenesis and microcirculation of high-grade glioma: an intravital multifluorescence microscopic approach in the athymic nude mouse. J Cereb Blood Flow Metab. 1998;18:510-520. (Pubitemid 28213535)
18. Pels H, Schulz H, Schlegel U, Engert A. Treatment of CNS lymphoma with the anti-CD20 antibody rituximab. Onkologie. 2003;26:351-354.
19. Rubenstein JL, Combs D, Rosenberg J, et al. Rituximab therapy for CNS lymphomas: targeting the leptomeningeal compartment. Blood. 2003;101:466-468. (Pubitemid 36077565)
20. Rubenstein JL, Fridlyand J, Abrey L, et al. Phase I study of intraventricular administration of rituximab in patients with recurrent CNS and intraocular lymphoma. J Clin Oncol. 2007;25:1350-1356. (Pubitemid 46706881)
21. Takami A, Hayashi T, Kita D, Nishimura R, Asakura H, Nakao S. Treatment of primary central nervous system lymphoma with induction of complement-dependent cytotoxicity by intraventricular administration of autologous-serum-supplemented rituximab. Cancer Sci. 2006;97:80-83. (Pubitemid 43257031)
22. Antonini G, Cox MC, Montefusco E, et al. Intrathecal anti-CD20 antibody: an effective and safe treatment for leptomeningeal lymphoma. J Neurooncol. 2007;81:197-199. (Pubitemid 44963979)
23. Schulz H, Pels H, Schmidt-Wolf I, Zeelen U, Germing U, Engert A. Intraventricular treatment of relapsed central nervous system lymphoma with the anti-CD20 antibody rituximab. Haematologica. 2004;89:753-754. (Pubitemid 38828486)
24. Bergman Y, Haimovich J. Characterization of a carcinogen-induced murine B lymphocyte cell line of C3H origin. Eur J Immunol. 1977;7:413-417. (Pubitemid 8149366)
25. Thielemans K, Rothbard JB, Levy S, Levy R. Syngeneic antiidiotypic immune responses to a B cell lymphoma: comparison between heavy chain hypervariable region peptides and intact Ig as immunogens. J Exp Med. 1985;162:19-34. (Pubitemid 15043974)
26. Golay J, Cittera E, Di Gaetano N, et al. The role of complement in the therapeutic activity of rituximab in a murine B lymphoma model homing in lymph nodes. Haematologica. 2006;91:176-183. (Pubitemid 43304136)
27. Hsu SM, Raine L. Fanger H. Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures. J Histochem Cytochem. 1981;29:577-580. (Pubitemid 11147380)
28. Nussenblatt RB, Chan CC, Wilson WH, Hochman J, Gottesman M; CNS and Ocular Lymphoma Workshop Group. International Central Nervous System and Ocular Lymphoma Workshop: recommendations for the future. Ocul Immunol Inflamm. 2006;14:139-144.
29. Grenn WR, Sebag J. Vitreoretinal interface. In: Ryan, Hintonn Schachat, Wilkinson, eds. Retina. 4th ed. St. Louis: Elsevier Mosby; 2006:1921-1989.
30. Yu DY, Cringle SJ, Yu PK, Su EN. Intraretineal oxygen distribution and consumption during retinal artery occlusion and graded hyperoxic ventilation in the rat. Invest Ophthalmol Vis Sci. 2007;48:2290-2296.
31. Chamberlain MC. Lymphomatous meningitis in primary central nervous system lymphoma. Neurosurg Focus. 2006;21(5):E6.
32. Paulus W. Classification, pathogenesis and molecular pathology of primary CNS lymphomas. J Neurooncol. 1999;43:203-208. (Pubitemid 29488376)
33. Martínez-Murillo R, Martínez A. Standardization of an orthotopic mouse brain tumor model following transplantation of CT-2A astrocytoma cells. Histol Histopathol. 2007;22:1309-1326. (Pubitemid 47470324)
34. Akpek EK, Ahmed I, Hochberg FH, et al. Intraocular-central nervous system lymphoma: clinical features, diagnosis, and outcomes. Ophthalmology. 1999;106:1805-1810. (Pubitemid 30194285)
35. Cassoux N, Merle-Beral H, Leblond V, et al. Ocular and central nervous system lymphoma: clinical features and diagnosis. Ocul Immunol Inflamm. 2000;8:243-250. (Pubitemid 32174745)
36. Touitou V, Daussy C, Bodaghi B, et al. Impaired Th1/Tc1 cytokine production of tumor-infiltrating lymphocytes in a model of primary intraocular B-cell lymphoma. Invest Ophthalmol Vis Sci. 2007;48:3223-3229. (Pubitemid 351261167)
37. Li Z, Mahesh SP, Shen de F, et al. Eradication of tumor colonization and invasion by a B cell-specific immunotoxin in a murine model for human primary intraocular lymphoma. Cancer Res. 2006;66:10586-10593. (Pubitemid 44799782)
38. Kim H, Csaky KG, Chan CC, et al. The pharmacokinetics of rituximab following an intravitreal injection. Exp Eye Res. 2006;82:760-766. (Pubitemid 43170877)
39. Harjunpaa A, Wiklund T, Collan J, et al. Complement activation in circulation and central nervous system after rituximab (anti-CD20) treatment of B-cell lymphoma. Leuk Lymphoma. 2001;42:731-738. (Pubitemid 32782781)
40. Wong ET, Tishler R, Barron L, Wu JK. Immunochemotherapy with rituximab and temozolomide for central nervous system lymphomas. Cancer. 2004;101:139-145. (Pubitemid 38812433)
41. Golay J, Zaffaroni L, Vaccari T, et al. Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis. Blood. 2000;95:3900-3908. (Pubitemid 30412866)
42. Clynes RA, Towers TL, Prest LG, Ravetch JV. Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nat Med. 2000;6:443-446. (Pubitemid 30208162)
43. Glennie MJ, French RR, Cragg MS, Taylor RP. Mechanisms of killing by anti-CD20 monoclonal antibodies. Mol Immunol. 2007;44:3823-3837.
44. Grisanti S, Wiedemann P, Weller M, Heimann K, Zilles K. The significance of complement in proliferative vitreoretinopathy. Invest Ophthalmol Vis Sci. 1991;32:2711-2717.
45. Van Beek J, Leward K, Gasque P. Activation of complement in the central nervous system. Ann N Y Acad Sci. 2003;992:56-71.
46. Chan CC, Fischette M, Shen D, Mahesh SP, Nussenblatt RB, Hochman J. Murine model of primary intraocular lymphoma. Invest Ophthalmol Vis Sci. 2005;46:415-419. (Pubitemid 40270316)